List of Denali Therapeutics patents

Patents where

Current Assignee

Name

Denali Therapeutics

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 11370832 Anti-Tau antibodies and methods of use thereof	Patent 11370832 was granted and assigned to Denali Therapeutics on June, 2022 by the United States Patent and Trademark Office.	Denali Therapeutics	Denali Therapeutics	United States Patent and Trademark Office	11370832	June 28, 2022
‌ US Patent 10457717 Engineered polypeptides	Patent 10457717 was granted and assigned to Denali Therapeutics on October, 2019 by the United States Patent and Trademark Office.	Denali Therapeutics	Denali Therapeutics	United States Patent and Trademark Office	10457717	October 29, 2019
‌ US Patent 11643446 Progranulin variants	Patent 11643446 was granted and assigned to Denali Therapeutics on May, 2023 by the United States Patent and Trademark Office.	Denali Therapeutics	Denali Therapeutics	United States Patent and Trademark Office	11643446	May 9, 2023
‌ US Patent 9932325 Compounds, compositions, and methods	Patent 9932325 was granted and assigned to Denali Therapeutics on April, 2018 by the United States Patent and Trademark Office.	Denali Therapeutics	Denali Therapeutics	United States Patent and Trademark Office	9932325	April 3, 2018
‌ US Patent 11306077 Compounds, compositions and methods	Patent 11306077 was granted and assigned to Denali Therapeutics on April, 2022 by the United States Patent and Trademark Office.	Denali Therapeutics	Denali Therapeutics	United States Patent and Trademark Office	11306077	April 19, 2022
‌ US Patent 11124567 Anti-TREM2 antibodies and methods of use thereof	Patent 11124567 was granted and assigned to Denali Therapeutics on September, 2021 by the United States Patent and Trademark Office.	Denali Therapeutics	Denali Therapeutics	United States Patent and Trademark Office	11124567	September 21, 2021
‌ US Patent 10143187 Transferrin receptor transgenic models	Patent 10143187 was granted and assigned to Denali Therapeutics on December, 2018 by the United States Patent and Trademark Office.	Denali Therapeutics	Denali Therapeutics	United States Patent and Trademark Office	10143187	December 4, 2018
‌ US Patent 11591316 Compounds, compositions, and methods	Patent 11591316 was granted and assigned to Denali Therapeutics on February, 2023 by the United States Patent and Trademark Office.	Denali Therapeutics	Denali Therapeutics	United States Patent and Trademark Office	11591316	February 28, 2023
‌ US Patent 9896458 Compounds, compositions and methods	Patent 9896458 was granted and assigned to Denali Therapeutics on February, 2018 by the United States Patent and Trademark Office.	Denali Therapeutics	Denali Therapeutics	United States Patent and Trademark Office	9896458	February 20, 2018
‌ US Patent 10131676 Compounds, compositions and methods	Patent 10131676 was granted and assigned to Denali Therapeutics on November, 2018 by the United States Patent and Trademark Office.	Denali Therapeutics	Denali Therapeutics	United States Patent and Trademark Office	10131676	November 20, 2018
‌ US Patent 11236100 Modulators of eukaryotic initiation factor 2B, compositions and methods	Patent 11236100 was granted and assigned to Denali Therapeutics on February, 2022 by the United States Patent and Trademark Office.	Denali Therapeutics	Denali Therapeutics	United States Patent and Trademark Office	11236100	February 1, 2022
‌ US Patent 11203600 Kinase inhibitors and uses thereof	Patent 11203600 was granted and assigned to Denali Therapeutics on December, 2021 by the United States Patent and Trademark Office.	Denali Therapeutics	Denali Therapeutics	United States Patent and Trademark Office	11203600	December 21, 2021
‌ US Patent 11174262 Compounds, compositions and methods	Patent 11174262 was granted and assigned to Denali Therapeutics on November, 2021 by the United States Patent and Trademark Office.	Denali Therapeutics	Denali Therapeutics	United States Patent and Trademark Office	11174262	November 16, 2021
‌ US Patent 9815850 Compounds, compositions and methods	Patent 9815850 was granted and assigned to Denali Therapeutics on November, 2017 by the United States Patent and Trademark Office.	Denali Therapeutics	Denali Therapeutics	United States Patent and Trademark Office	9815850	November 14, 2017
‌ US Patent 11072618 Compounds, compositions and methods	Patent 11072618 was granted and assigned to Denali Therapeutics on July, 2021 by the United States Patent and Trademark Office.	Denali Therapeutics	Denali Therapeutics	United States Patent and Trademark Office	11072618	July 27, 2021
‌ US Patent 10870837 Fusion proteins comprising enzyme replacement therapy enzymes	Patent 10870837 was granted and assigned to Denali Therapeutics on December, 2020 by the United States Patent and Trademark Office.	Denali Therapeutics	Denali Therapeutics	United States Patent and Trademark Office	10870837	December 22, 2020
‌ US Patent 9802927 Oxadiazine compounds and methods of use thereof	Patent 9802927 was granted and assigned to Denali Therapeutics on October, 2017 by the United States Patent and Trademark Office.	Denali Therapeutics	Denali Therapeutics	United States Patent and Trademark Office	9802927	October 31, 2017
‌ US Patent 11028080 Substituted pyrimidines as LRKK2 inhibitors	Patent 11028080 was granted and assigned to Denali Therapeutics on June, 2021 by the United States Patent and Trademark Office.	Denali Therapeutics	Denali Therapeutics	United States Patent and Trademark Office	11028080	June 8, 2021
‌ US Patent 11214565 Compound, compositions, and methods	Patent 11214565 was granted and assigned to Denali Therapeutics on January, 2022 by the United States Patent and Trademark Office.	Denali Therapeutics	Denali Therapeutics	United States Patent and Trademark Office	11214565	January 4, 2022
‌ US Patent 9771378 Fused morpholinopyrimidines and methods of use thereof	Patent 9771378 was granted and assigned to Denali Therapeutics on September, 2017 by the United States Patent and Trademark Office.	Denali Therapeutics	Denali Therapeutics	United States Patent and Trademark Office	9771378	September 26, 2017
‌ US Patent 10851088 Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production		Denali Therapeutics	Denali Therapeutics	United States Patent and Trademark Office	10851088	December 1, 2020
‌ US Patent 10370361 Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production	Patent 10370361 was granted and assigned to Denali Therapeutics on August, 2019 by the United States Patent and Trademark Office.	Denali Therapeutics	Denali Therapeutics	United States Patent and Trademark Office	10370361	August 6, 2019
‌ US Patent 11111235 Compounds, compositions, and methods	Patent 11111235 was granted and assigned to Denali Therapeutics on September, 2021 by the United States Patent and Trademark Office.	Denali Therapeutics	Denali Therapeutics	United States Patent and Trademark Office	11111235	September 7, 2021
‌ US Patent 10709692 Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1)		Denali Therapeutics	Denali Therapeutics	United States Patent and Trademark Office	10709692	July 14, 2020
‌ US Patent 10604535 Compounds, compositions and methods	Patent 10604535 was granted and assigned to Denali Therapeutics on March, 2020 by the United States Patent and Trademark Office.	Denali Therapeutics	Denali Therapeutics	United States Patent and Trademark Office	10604535	March 31, 2020

Results per page:

39 results

0 selected

39 results

0 selected